| Literature DB >> 29844876 |
Hirotaka Ota1,2, Takashi Shionome3, Hisashi Suguro4,5, Satsuki Saito6, Kosuke Ueki6, Yoshinori Arai7, Masatake Asano1,2.
Abstract
The effect of NiCl2 on oral squamous cell carcinoma-derived cell line HSC3 was examined. Incubation with 1 mM NiCl2 significantly reduced the expression of MMPs at mRNA and protein levels. The in vivo orthotopic implantation model was established by injecting highly metastatic subcell line HSC3-M3 to nude mouse tongue. After 1 week of injection, mice were fed with or without 1 mM NiCl2-containing water for two to three weeks. Immunohistochamical examination revealed that MMP9 expression was drastically reduced in NiCl2-fed mice. By CT images, cancer mass was observed as a translucent area in control mice. In NiCl2-fed mice, much highly translucent area was observed within the translucent area. Histologically, this area corresponded to the necrotic area in the tumor mass. Real-time PCR analysis revealed the reduced expression of angiogenic factors such as IL-8 and VEGF mRNA in NiCl2-fed mice. To further examine the effect of NiCl2 on metastasis, human β-globin gene expression in regional lymphnodes was compared. The β-globin gene was totaly absent in NiCl2-fed mice. Moreover, various cancer metastasis-related genes were inhibited in NiCl2-fed mice by PCR array analysis. The results indicated that NiCl2 might be a promising new anti-cancer therapeutics for the oral cancer treatment.Entities:
Keywords: matrix metalloproteinase; nickel chloride; nuclear factor-kappa B; nude mouse; oral squamous cell carcinoma
Year: 2018 PMID: 29844876 PMCID: PMC5963632 DOI: 10.18632/oncotarget.25313
Source DB: PubMed Journal: Oncotarget ISSN: 1949-2553
Figure 1Inhibition of MMP expression following Ni2+-treatment
(A) HSC3 cells and other squamous cell carcinoma cell lines (HSC1, 2 and 5) were cultured with or without NiCl2 (1 mM) for 24 h. The total RNA was purified and subjected to real-time PCR. MMPs expression in the cells cultured without Ni2+ was set as 1. The mean ± standard deviation (SD) of three separate experiments are shown. (*p < 0.05). (B) HSC3 cells were cultured with or without 1mM Ni2+ for 24 h. At the end of culture, the cell lysates were harvested and subjected to immunoprecipitation using anti-MMP9Ab (upper panel) or anti-GAPDH Ab (lower panel), followed by protein G-sepharose. The samples were separated with 10% SDS-PAGE and further subjected to Western blotting. Mouse anti-human MMP9 Ab or mouse anti-human GAPDH Ab followed by HRP-labelled goat anti-mouse IgG (H+L) Ab were used. The data is representative of three independent experiments.
Figure 2Ni2+ inhibited the NF-κB activity
(A) Wild type 5′-UTR of the MMP9 gene was fused to luciferase reporter construct (WT). The upper (Δ upper) and lower (Δ lower) NF-κB binding sites were deleted by site-directed mutagenesis. (B) HSC3 cells were transfected with WT or (C) Δ upper or Δ lower along with pRL/CMV vector for 5 h. The cells were further cultured for 18 h and stimulated with or without 1 mM Ni2+ for 12 h or 24 h. At the end of stimulation, the cells were lysed with passive lysis buffer and luciferase activity was measured. The mean ± SD of three independent experiments was shown. (*p < 0.05).
Figure 3Addition of 1 mM NiCl2 in drinking water inhibited MMP9 expression
HSC3 cells were xenografted to the tongue of nude mice. After tumor mass formation, mice were fed with regular drinking water (n = 5) or 1 mM NiCl2-containing water (n = 7) for 1 week. (A) The tissue was excised, formalin-fixed and embedded in paraffin. The expression of MMP9 was examined by immunohistochemical staining using anti-MMP9 Ab as the first Ab. (B) The excised tissue were minced, lysed with cell lysis buffer and subjected to IP-Western. Representatives of three independent experiments were shown for both (A and B).
Figure 4Production of hyper-lucent areas within the cancer mass
(A) HSC3-M3 cells (5 × 105/30 μl) were injected into nude mice tongue. After cancer mass formation (1 week), mice were fed with (n = 5) or without 1 mM NiCl2-containing water (n = 7) for 2 weeks. A contrast agent was injected into the tail vein and CT images of the primary regions were obtained. Left panel: regular water, arrowheads indicate the translucent area. Right panel: NiCl2, The hyper translucent area can be observed in the translucent area. The representative of 5 (non-fed) and 7 (Ni2+-fed) different images was shown. (B) The primary region was excised, fixed and embedded in paraffin. The specimens were stained by H&E staining. Left panel: regular water. Right panel: NiCl2-containing water. The arrows indicate the necrotic area. Representative data of at least five different experiments for each group are shown. (C) RNA was extracted from the tongue tissues and subjected to real-time PCR to examine IL-8 and VEGF expression. The mean ± SD of three separate experiments are shown. (*p < 0.05).
Figure 5Anti-metastatic effect of Ni2+
(A) After 2 weeks of breeding with 1 mM NiCl2-containing water or regular water, primary tongue regions (upper panel) and lymph nodes (lower panel) were excised from 6 mice of each group. Genomic DNA was purified and subjected to PCR for β-globin gene. The representative of 6 separate experiments were shown. (B) RNA was purified from the tongue tissues obtained from nude mice fed with (n = 3) or without NiCl2-containing water (n = 3). PCR array was performed with RT2 Profiler PCR Array kit (QIAGEN) to examine the expression levels of the cancer metastatic genes. Expression levels of each gene relative to those in the Ni2+ non-fed control mice are shown. The representative of 2 different experiments were shown.
The genes analysed in this study
| Official Symbol | Official Full Name | Official Symbol | Official Full Name |
|---|---|---|---|
| Apc | adenomatosis polyposis coli | Kras | Kirsten rat sarcoma viral oncogene homolog |
| Brms1 | breast cancer metastasis-suppressor 1 | Lpar6 | lysophosphatidic acid receptor 6 |
| Cd7 | chemokine (C-C motif) ligand 7 | Mcam | melanoma cell adhesion molecule |
| Cdh1 | cadherin 1 | Mdm2 | transformed mouse 3T3 cell double minute 2 |
| Cdh11 | cadherin 11 | Mmp10 | matrix metallopeptidase 10 |
| Cdh6 | cadherin 6 | Mmp11 | matrix metallopeptidase 11 |
| Cdh8 | cadherin 8 | Mmp13 | matrix metallopeptidase 13 |
| Cdkn2a | cyclin-dependent kinase inhibitor 2A | Mmp2 | matrix metallopeptidase 2 |
| Cdh4 | chromodomain helicase DNA binding protein 4 | Mmp3 | matrix metallopeptidase 3 |
| Col4a2 | collagen, type IV, alpha 2 | Mmp7 | matrix metallopeptidase 7 |
| Csf1 | colony stimulating factor 1 | Mmp9 | matrix metallopeptidase 9 |
| Ctbp1 | C-terminal binding protein 1 | Mta1 | metastasis associated 1 |
| Ctnna1 | catenin (cadherin associated protein), alpha 1 | Mtss1 | metastasis suppressor 1 |
| Ctsk | cathepsin K | Myc | myelocytomatosis oncogene |
| Ctsl | cathepsin L | MycI | v-myc avian myelocytomatosis viral oncogene lung carcinoma derived |
| Cxcl12 | chemokine (C-X-C motif) ligand 12 | Nf2 | neurofibromin 2 |
| Cxcr2 | chemokine (C-X-C motif) receptor 2 | Nme1 | NME/NM23 nucleoside diphosphate kinase 1 |
| Cxcr4 | chemokine (C-X-C motif) receptor 4 | Nme2 | NME/NM23 nucleoside diphosphate kinase 2 |
| Denr | density-regulated protein | Nme4 | NME/NM23 nucleoside diphosphate kinase 4 |
| Elane | elastase | Nr4a3 | nuclear receptor subfamily 4, group A, member 3 |
| Ephb2 | Eph receptor B2 | Plaur | plasminogen activator, urokinase receptor |
| Etv4 | ets variant 4 | Pnn | pinin |
| Ewsr1 | Ewing sarcoma breakpoint region 1 | Pten | phosphatase and tensin homolog |
| Fat1 | FAT atypical cadherin 1 | Rb1 | RB transcriptional corepressor 1 |
| Fgfr4 | fibroblast growth factor receptor 4 | Rorb | RAR-related orphan receptor beta |
| Flt4 | FMS-like tyrosine kinase 4 | Rpsa | ribosomal protein SA |
| Fn1 | fibronectin 1 | Set | SET nuclear oncogene |
| Fxyd5 | FXYD domain-containing ion transport regulator 5 | Smad2 | SMAD family member 2 |
| Gpnmb | glycoprotein (transmembrane) nmb | Smad4 | SMAD family member 4 |
| Hgf | hepatocyte growth factor | Src | Rous sarcoma oncogene |
| Hpse | heparanase | Sstr2 | somatostatin receptor 2 |
| Hras | Harvey rat sarcoma virus oncogene | Syk | spleen tyrosine kinase |
| Htatip2 | HIV-1 Tat interactive protein 2 | Tcf20 | transcription factor 20 |
| Igf1 | insulin-like growth factor 1 | Tgfb1 | transforming growth factor, beta 1 |
| II18 | interleukin 18 | Timp2 | tissue inhibitor of metalloproteinase 2 |
| II1b | interleukin 1 beta | Timp3 | tissue inhibitor of metalloproteinase 3 |
| Itga7 | integrin alpha 7 | Timp4 | tissue inhibitor of metalloproteinase 4 |
| Itgb3 | integrin beta 3 | Tnfsf10 | tumor necrosis factor (ligand) superfamily, member 10 |
| Kiss1 | KiSS-1 metastasis-suppressor | Trp53 | transformation related protein 53 |
| Kiss1r | KISS1 receptor | Tshr | thyroid stimulating hormone receptor |
| Vegfa | vascular endothelial growth factor A |
The primers used in this study
| Primer | Sequence | ||
|---|---|---|---|
| MMP9 | Forward | 5′-GGG ACG CAG ACA TCG TCA TC-3′ | Real-time PCR |
| Reverse | 5′-TCG TCA TCG TCG AAA TGG GC-3′ | ||
| β-actin | Forward | 5′-GGA GCA AGT ATC TTG ATC TTC-3′ | |
| Reverse | 5′-CCT TCC TGC GCA TGG AGT CCT G-3′ | ||
| IL-8 | Forward | 5′-CCA GCC ATC AGC CAT GAG GGT-3′ | |
| Reverse | 5′-GGA GCC CTT TCT GAA TCC GCA-3′ | ||
| VEGF | Forward | 5′-GCA CCC ATG GCA GAA GG-3′ | |
| Reverse | 5′-CTC GAT TGG ATG GCA GTA GCT-3′ | ||
| MMP9 | Forward | 5′-GTG GAA TTC CCC AGA CTT GCC TA-3′ | Luciferase assay |
| Reverse | 5′-GGT GAG GGC AGA GGT GTC TGA-3′ | ||
| GH20 | Forward | 5′-GAA GAG CCA AGG ACA GGT AC-3′ | nested-PCR |
| GH21 | Reverse | 5′ GGA AAA TAG ACC AAT AGG CGA-3′ | |
| KM29 | Forward | 5′-GGT TGG CCA ATC TAC TCC CAG G-3′ | |
| KM38 | Reverse | 5′-TGG TCT CCT TAA ACC TGT CTT G-3′ |